<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131231">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034877</url>
  </required_header>
  <id_info>
    <org_study_id>B1851140</org_study_id>
    <nct_id>NCT02034877</nct_id>
  </id_info>
  <brief_title>13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India</brief_title>
  <official_title>A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 50 TO 65 YEARS OF AGE AND IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>India: New Drug Advisory Committee</authority>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65
      years of age and in Indian children 6 to 17 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The proportion of subjects reporting adverse events (AEs) and serious adverse events (SAEs) within approximately 1 month after 13vPnC administration.</measure>
    <time_frame>Baseline to 1 month post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) within approximately 1 month after 13vPnC administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional antibody titers as measured by serotype-specific opsonophagocytic activity (OPA) assays before and approximately 1 month after 13vPnC administration.</measure>
    <time_frame>Baseline to 1 month post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the immune responses to the 13 pneumococcal serotypes induced by 13vPnC</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal conjugate vaccine</intervention_name>
    <description>1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>10 mL of blood will be collected just before and approximately 1 month after vaccination.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Indian adults subjects between 50 and 65 years of age and indian children between 6 and
        17years of age, determined by clinical judgment to be eligible for 13vPnC vaccination.

        Exclusion Criteria:

        Any contraindication to 13vPnC vaccination, vaccination with any pneumococcal vaccine
        within the last year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851140&amp;StudyName=13-valent%20pneumococcal%20conjugate%20vaccine%20study%20in%20adults%20and%20children%20in%20India%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>January 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>13-valent pneunococcal conjugate vaccine</keyword>
  <keyword>pneumococcal disease prevention; safety and immunogenicity study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
